Nuo Therapeutics Selected to Exhibit Aurix® System at Vizient Innovative Technology Exchange
June 26, 2023 15:00 ET
|
Nuo Therapeutics, Inc.
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on...
Nuo Therapeutics’ Aurix® System Added To Wound Care Formulary Of Wound Care Advantage
June 22, 2023 08:30 ET
|
Nuo Therapeutics, Inc.
HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on...
Nuo Therapeutics Provides Corporate and Business Update
August 30, 2022 08:30 ET
|
Nuo Therapeutics, Inc.
Broad equity incentive agreement established with Pacific Medical, Inc. including initial equity purchase Favorable initial progress on establishing substantive distribution network in support of...
Nuo Therapeutics Responds to Mini-Tender Offer
February 04, 2022 17:53 ET
|
Nuo Therapeutics, Inc.
HOUSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (“Nuo” or the “Company”) announced that it is aware of an unsolicited “mini-tender” offer by Alternative Liquidity Index, LP to...
Nuo Therapeutics Receives Advisory Opinion Waiver for Medicare Part B Co-Payments for Patients in Aurix CED Clinical Studies
July 05, 2017 08:00 ET
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., July 05, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) (“Nuo” or the “Company”) announced today that the Office of Inspector General (OIG) of Department of Health...
Nuo Therapeutics Restructures Series A Preferred Stock with Deerfield
June 12, 2017 16:00 ET
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., June 12, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) (the “Company”) announced today that it entered into an Exchange Agreement with entities affiliated with...
Nuo Therapeutics Obtains Stockholder Consent to Reverse Split
May 08, 2017 16:49 ET
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., May 08, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) (the “Company”) announces receipt of the written consent of more than a majority of the voting power of its...
Nuo Therapeutics Appoints Dr. Paul D. Mintz to its Board of Directors
April 10, 2017 06:00 ET
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., April 10, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) (“Nuo” or the “Company”) announces the appointment of Paul D. Mintz, MD, Senior Vice President and Chief...
Nuo Therapeutics Provides Update on Public Market Trading Status
March 06, 2017 14:41 ET
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., March 06, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB:AURX) (“Nuo” or the “Company”), announced today that the Depository Trust Company (“DTC”) has approved the...
Nuo Therapeutics Announces Execution of Third Limited Consent With Deerfield Management Through January 7, 2016
December 18, 2015 17:15 ET
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:NUOT), today announced that the Company has entered into a third limited consent with Deerfield Management, L.P....